Imidazopyrimidines, potent inhibitors of p38 MAP kinase

被引：267

作者：

Rupert, KC ^{[1
]}

Henry, JR ^{[1
]}

Dodd, JH ^{[1
]}

Wadsworth, SA ^{[1
]}

Cavender, DE ^{[1
]}

Olini, GC ^{[1
]}

Fahmy, B ^{[1
]}

Siekierka, JJ ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, LLC, Drug Discovery, Raritan, NJ 08869 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 03期

关键词：

D O I：

10.1016/S0960-894X(02)01020-X

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：347 / 350

页数：4

共 50 条

[1] Potent inhibitors of the map kinase p38
Henry, JR
Rupert, KC
Dodd, JH
Turchi, IJ
Wadsworth, SA
Cavender, DE
Schafer, PH
Siekierka, JJ
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) : 3335 - 3340
[2] Substituted isoxazoles as potent inhibitors of p38 MAP kinase
Laufer, Stefan A.
Margutti, Simona
Fritz, Martina D.
CHEMMEDCHEM, 2006, 1 (02) : 197 - 207
[3] Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase
Tamayo, N
Liao, L
Goldberg, M
Powers, D
Tudor, YY
Yu, V
Wong, LM
Henkle, B
Middleton, S
Syed, R
Harvey, T
Jang, G
Hungate, R
Dominguez, C
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (09) : 2409 - 2413
[4] Inhibitors of p38α MAP kinase
Chakravarty, S
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37, 2002, 37 : 177 - 186
[5] Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase
Cumming, JG
McKenzie, CL
Bowden, SG
Campbell, D
Masters, DJ
Breed, J
Jewsbury, PJ
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (21) : 5389 - 5394
[6] The development p38 MAP kinase inhibitors
Hynes, John
Wu, H.
Dyckman, A. J.
Lin, S.
Wrobleski, S. T.
Gillooly, K. M.
McIntyre, K. W.
Pitt, S.
Shen, D. R.
Shuster, D. J.
Xia, X.
Zhang, R.
INFLAMMATION RESEARCH, 2007, 56 : S474 - S474
[7] Inhibitors of unactivated p38 MAP kinase
Bullington, James
Argentieri, Dennis
Averill, Kristin
Carter, Demetrius
Cavender, Druie
Fahmy, Bohumila
Fan, Xiaodong
Hall, Daniel
Heintzelman, Geoffrey
Jackson, Paul
Leung, Wai-Ping
Li, Xun
Ling, Ping
Olini, Gilbert
Razler, Thomas
Reuman, Michael
Rupert, Kenneth
Russell, Ronald
Siekierka, John
Wadsworth, Scott
Wolff, Russell
Xiang, Bangping
Zhang, Yue-Mei
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (23) : 6102 - 6106
[8] Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase
Stelmach, JE
Liu, LP
Patela, SB
Pivnichny, JV
Scapin, G
Singh, S
Hop, CECA
Wang, Z
Strauss, JR
Cameron, PM
Nichols, EA
O'Keefe, SJ
O'Neill, EA
Schmatz, DM
Schwartz, CD
Thompson, CM
Zaller, DM
Doherty, JB
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (02) : 277 - 280
[9] Novel inhibitors of p38 MAP kinase.
Shetty, R
Moffett, KK
Nguyen, D
Kelly, MJ
Michelotti, EL
Dorsey, BD
Springman, E
Bukhtiyarova, M
Northrop, K
Chai, XM
Saporito, MS
Ochman, AR
Karpusas, M
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U947 - U947
[10] Benzothiazole based inhibitors of p38α MAP kinase
Liu, Chunjian
Lin, James
Pitt, Sidney
Zhang, Rosemary F.
Sack, John S.
Kiefer, Susan E.
Kish, Kevin
Doweyko, Arthur M.
Zhang, Hongjian
Marathe, Punit H.
Trzaskos, James
Mckinnon, Murray
Dodd, John H.
Barrish, Joel C.
Schieven, Gary L.
Leftheris, Katerina
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) : 1874 - 1879

← 1 2 3 4 5 →